|
|
Blood, 1 January 2005, Vol. 105, No. 1, pp. 77-84.
Prepublished online as a Blood First Edition Paper on July 8, 2004; DOI 10.1182/blood-2003-12-4445.
 Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS
Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis
Ki Young Chung,
Giovanni Morrone,
Jan Jacob Schuringa,
Bryan Wong,
David C. Dorn, and
Malcolm A. S. Moore
From the Laboratory of Developmental Hematopoiesis, Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY; and the Department of Experimental and Clinical Medicine, University of Catanzaro "Magna Graecia," Catanzaro, Italy.
To investigate the role of constitutively active internal tandem duplication (ITD) mutants of the Fms-like tyrosine kinase 3 (Flt3) receptor in leukemogenesis, we introduced the Flt3-ITD, W51, into human cord blood CD34+ cells and evaluated their phenotype in diverse hematopoietic assays. W51 expression resulted in a strong proliferative advantage and enhanced erythropoiesis as determined by immunophenotyping, colony assays, and molecular analyses. In MS-5 stromal cocultures, numerous early cobblestone areas (CAs) were generated within 10 to 14 days. Such W51-associated early CAs disappeared by 4 weeks, yet retained self-renewal properties as demonstrated by generation of secondary and tertiary CAs upon replating. This phenotype appears related to the expression of W51 since it was abolished by exposure to the FLT3 inhibitor, AG1295, but not to the c-kit inhibitor PD16. Wild-type Flt3–overexpressing CD34+ cells exposed to high levels of its physiologic ligand did not produce early CAs, highlighting differences in intracellular signaling between wild-type Flt3 and W51. W51-associated signal transducer and activator of transcription 5 (Stat5) activation plays a major role in this phenotype, although additional downstream targets of W51 may be relevant. Flt3-ITD+ acute myeloid leukemia (AML) blasts from patients invariably generated early AG1295-sensitive CAs in MS-5 cocultures, further validating the phenotype observed in transduced CD34+ cells.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Rizo, B. Dontje, E. Vellenga, G. de Haan, and J. J. Schuringa
Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1
Blood,
March 1, 2008;
111(5):
2621 - 2630.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Choudhary, C. Brandts, J. Schwable, L. Tickenbrock, B. Sargin, A. Ueker, F.-D. Bohmer, W. E. Berdel, C. Muller-Tidow, and H. Serve
Activation mechanisms of STAT5 by oncogenic Flt3-ITD
Blood,
July 1, 2007;
110(1):
370 - 374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Y. Chung, G. Morrone, J. J. Schuringa, M. Plasilova, J.-H. Shieh, Y. Zhang, P. Zhou, and M. A.S. Moore
Enforced Expression of NUP98-HOXA9 in Human CD34+ Cells Enhances Stem Cell Proliferation
Cancer Res.,
December 15, 2006;
66(24):
11781 - 11791.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Rizo, E. Vellenga, G. de Haan, and J. J. Schuringa
Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche?
Hum. Mol. Genet.,
October 15, 2006;
15(suppl_2):
R210 - R219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. J. Wierenga, H. Schepers, M. A. S. Moore, E. Vellenga, and J. J. Schuringa
STAT5-induced self-renewal and impaired myelopoiesis of human hematopoietic stem/progenitor cells involves down-modulation of C/EBP{alpha}
Blood,
June 1, 2006;
107(11):
4326 - 4333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Licht and D. W. Sternberg
The Molecular Pathology of Acute Myeloid Leukemia
Hematology,
January 1, 2005;
2005(1):
137 - 142.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
